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a,-Proteinase inhibitor (a,-PI)' is a member ofthe serpin group of serine pro-
teinase inhibitors (1, 2). Based on inhibitory kinetics, the principal target of a,-
PI is human leukocyte elastase (HLE) (3). The metalloproteinase elastase
secreted by mouse macrophages inactivates a,-PI (4) by hydrolyzing the Pro-
357-Met-358 bond (5), which results in Mr 47,800 and Mr 4,200 fragments. We
recently observed that a,-PI proteolytically inactivated by mouse macrophage
elastase becomes a potent chemotactic factor for human neutrophils (6) . After
proteolysis, the 47,800 and 4,200 fragments of a,-PI remain associated with
each other in a bimolecular complex, with the chemotactic activity residing in a
newly exposed region of the 4,200 fragment (6).
When HLE is inactivated by a,-PI, the Met-358-Ser-359 bond is hydrolyzed,
resulting in a COOH-terminal cleavage fragment very similar to that generated
by mouse macrophage elastase. In contrast to mouse macrophage elastase,
which does not form an inhibitory complex with a,-PI, HLE remains tightly
associated with a,-PI. Therefore, the HLE-al-PI complex actually consists of
three molecules: HLE and two fragments of a,-PI. Because it is likely that the
orientation of the two fragments of a,-PI in the HLE-a,-PI complex is similar
to that of the two a,-PI fragments generated after proteolysis by mouse macro-
phage elastase, we considered the possibility that the HLE-a,-PI complex pos-
sesses chemotactic activity similar to that of the proteolytically inactivated a,-PI.
In the study reported here, using homologous reagents, we examined the ability





Chemicals were purchased from the following sources: human a,-PI from
CalBiochem-Behring Corp., La Jolla, CA; human leukocyte elastase from Elastin Prod-
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ucts Co., Pacific, MO ; rabbit anti-a,-PI IgG and anti-a2-macroglobulin IgG from Sigma
Chemical Co., St. Louis, MO; prestained protein standards for SDS-PAGE from
Bethesda Research Laboratories, Gaithersburg, MD; and all reagents for electrophoresis
from Bio-Rad Laboratories, Richmond, CA. Sheep anti-HLE IgG was a gift of D. Burnett
and R. Stockley, The General Hospital, Birmingham, England.
HLE-a,-PI Complexes.
￿
Reaction mixtures containing HLE and a,-PI (1 :1, mol/mol)
were incubated at 37°C in a 10 mM phosphate buffer, pH 6 .8, for 15 min. The reaction




SDS-PAGE was performed according to the method of Laemmli (7)
using 12% resolving gels on a Mini-slab apparatus from Idea Scientific (Corvallis, OR).
After electrophoresis the protein bands were stained for 15 min with 0.5% (vol/vol)
Coomassie Blue R250 in acetic acid/isopropyl alcohol/water (1 :3 :6), destained with 50%
methyl alcohol, and silver stained according to Wray et al. (8) .
Cells.
￿
Neutrophils were separated on Ficoll-Paque gradients from peripheral blood
obtained from healthy volunteers (9).
Chemotaxis.
￿
Chemotaxis was determined in modified Boyden chambers, as previously
described (10, 11) . Briefly, 1 .2 X 106 neutrophils/ml were placed in the upper com-
partment and separated from chemoattractants in the lower compartment by a 2-Am
pore size filter (Nucleopore Corp., Pleasanton, CA) overlaying a 0 .45-jm pore size filter
(Millipore Corp., Bedford, MA). After 1 h the chambers were disassembled and the mem-
branes were stained with hematoxylin. Chemotaxis was quantified by counting at high
dry magnification (X 400) the number of cells that migrated to the interface between
the membranes (expressed as cells per high power grid). Five fields were counted for
each experiment, and the results were corrected for the number of cells migrating in
control chambers, which contained cells in the upper compartment and medium alone
in the lower compartment. Experiments were performed in triplicate.
Purification of HLE-a,-PI Complexes.
￿
Chromatography was performed on a liquid
chromatograph (model 1090; Hewlett-Packard Co., Palo Alto, CA) equipped with an
HP1040 photodiode array detector. Elutions were monitored at 280 nm. Samples of
HLE-a,-PI reaction mixtures were injected onto an AX-300 anion-exchange column (4 .6
X 250 mm) (Brownlee Labs, Santa Clara, CA) equilibrated with 5 mM Tris-HCI, pH 8.0
(solvent A), and developed with a gradient to 0 .8 M NaCI in solvent A (solvent B). The
gradient was delivered at 0.5 ml/min, as follows: 0-5 min, 0% B; 5-10 min, 0-20% B;
10-20 min, 20-25% B; 20-25 min, 25% B; 25-65 min, 25-65% B .
a,-PI Fragment.
￿
The M, 4,200 fragment of a,-PI was generated by hydrolysis of the




Purified HLE-a,-PI complex (100 Al, 10 -6 M) was incubated with 14 A1
of stock anti-a,-PI IgG, 2 jl of anti-HLE IgG, or 24 J1 of anti-a2-macroglobulin IgG
before use in a chemotactic assay. Controls were HLE-a,-PI complex incubated in assay
medium alone and FMLP incubated in assay medium alone or with anti-a,-PI IgG. All
incubations were at ambient temperature for 60 min.
Preexposure to Competitive Ligands. Neutrophils were incubated in 10 nM purified
HLE-a,-PI complex or 10 nM purified M, 4,200 fragment of a,-PI for 30 min at
ambient temperature, then washed three times with medium. The cells were then assayed
for a chemotactic response to 1 nM HLE-a,-PI complex, 1 nM 4,200 fragment, or 10
nM FMLP.
Results
Equal molar amounts of HLE and human a,-PI were incubated together at
37°C for 15 min, resulting in the formation of a stable HLE-a,-PI inhibitory
complex. Dilutions of this reaction mixture were assayed for their ability to stim-
ulate migration of human neutrophils in modified Boyden chambers. Migration1610
￿
CHEMOTAXIS TO PROTEINASE-INHIBITOR COMPLEXES
r
F
9 I :1 (a,-PI : MLE)
6 1:0.25 (0,-PE " : M6E)
O I :1(Q,-PI:HLE+PMSF)
FIGURE 1 . Stimulation of neutrophil chemotaxis by
reaction mixtures containing HLE-a,-PI complexes. a,-
PI was incubated for 15 min with HLE, 1 :1 mol/mol
(" ) ; HLE, 1 :0.25 mol/mol (A) ; or HLE (1 :1 mol/mol)
that had been inactivated with PMSF before incubation
(0). Dilutions of the reaction mixtures were then
assayed for their ability to stimulate chemotaxis of
human neutrophils. The points represent the average of
triplicate determinations, and the error bars represent
the standard errorof the mean . h.p .g ., high power grid .
Migration stimulated by 10-"M FMLP (the positive con-
trol) was 153 ± 4.2 cells .
was equivalent to that stimulated by 10 nM FMLP (the positive control) . Maxi-
mal stimulation of migration was achieved at a dilution equivalent to 1 nM a,-
PI initially added to the reaction mixture (Fig. 1) . Chemotaxis was reduced when
the proportion of HLE in the reaction mixture was reduced four-fold, suggest-
ing that the chemotactic activity was proportional to the HLE-a,-PI complex in
the reaction mixture . Neither native a,-PI nor HLE alone stimulated migration
of neutrophils .
In our previous study (6), proteolytically modified a,-PI was shown to be che-
motactic for neutrophils . In that study the metalloproteinase macrophage elas-
tase was used to degrade a,-PI because it would not form an inhibitory complex
(4, 5) . In the present study, a stable inhibitory complex was formed between
FtcURE 2.
￿
Purification ofHLE-a l -PI complex. a,-PI was incubated with an excess of HLE,
then applied to an AX-300 anion-exchange column equilibrated with 5 mM Tris-HCA, pH
8.0 . Absorbance was monitored at 280 run and expressed as milliabsorbance units (mAU).
The column was developed with a gradient of NaCl as described in Materials and Methods.
(Inset) Silver-stained SDS-polyacrylamide electrophoretic gel containing native a,-PI (M,
HL.E-a)-PI reaction mixture (R), and an aliquot of a fraction corresponding to peak C con-
















Stimulation of neutrophil chemo-
taxis by purified HLE-a,-PIcomplex. Purified
HLE-a,-PI complex obtained by anion-
exchange chromatography was assayed for its
ability to stimulate chemotaxis of human neu-
trophils. The points represent the average of
triplicate determinations, and the error bars
represent the standard error of the mean.
Migration stimulated by 10-" M FMLP was
127 ± 6.6 cells.
HLE and a,-PI. When HLE and a,-PI were incubated under conditions of
excess HLE, proteolytically modified complex and a,-PI were detected in addi-
tion to the classical inhibitory complex. To determine if the inhibitory complex
itself stimulated migration, the complex was purified. Equal molar amounts of
FILE and a,-PI were incubated together to form the inhibitory complex. The
reaction mixture was then fractionated on an AX-300 anion-exchange column,
and peak fractions were analyzed by electrophoresis. The HLE-a,-PI complex
eluted as a single band with an apparent M, of 80,300 (Fig. 2). Various concen-
trations of the purified complex were assayed for their ability to stimulate migra-
tion of neutrophils. Again, migration was equivalent to that stimulated by the
FMLP positive control (Fig. 3) . The optimal concentration of purified HLE-al-
PI complex was 1 nM, the same concentration that stimulated maximal migra-
tion when the crude reaction mixture was used (Fig. 1).
To distinguish chemotactic migration from chemokinetic migration, various
concentrations of purified HLE-al -PI complex were placed in the upper and
lower compartments of modified Boyden chambers during the migration assay.
A "checkerboard" analysis verified that HLE-al-PI complex stimulated che-
motaxis, because cells migrated only when there was a concentration gradient
(Table I) .
TABLE I
"Checkerboard" Analysis ofChemotaxis to HLE-al-PI Complex
HLE-a,-PI (M) in
lowercompartment
* Data are expressed as mean number of cells ± SE perhigh power grid.
HLE-a,-PI (M) in upper compartment
0 10 -" 10-'° 10 -1
10-" 34* 12 2 12
± 4.2 ± 2.4 ± 5.3 ± 3.6
10 -1° 74 14 8 17
± 4.2 ± 4.9 ± 2.8 ± 2.6
10 -" 168 102 64 26
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a,PI-Ab
FIGURE 4 . Effect of specific antibodies on
neutrophil chemotaxis . Purified HLE-a,-PI
complex was incubated for 60 min at ambient
temperature in assay medium (" ); with anti-
body against a,-PI (O) ; or with antibody
against HLE (A) before assay for the chemo-
tactic response . The points represent the aver-
age of triplicate determinations, and the error
bars represent thestandard error of the mean .
(Histogram) Before assay, FMLP was incubated
for 60 min at ambient temperature with
medium alone or with antibody against a,-PI .
h.p.g., high power grid.
Because the HLE-a,-PI complex contains elastase as well as a,-PI, it was pos-
sible that the chemotactic signal was associated with the elastase portion of the
complex . To test this possibility, purified HLE-a,-PI complex was separately
incubated with anti-a,-PI, anti-HLE, and anti-a2-macroglobulin antibodies
before use in the migration assay . The antibody against a,-PI inhibited chemo-
taxis, whereas antibody against HLE did not (Fig . 4) . Therefore, the chemotactic
signal was associated with a,-PI and not the elastase portion of the complex .
The lack of inhibition by anti-a2-macroglobulin antibody (data not shown) dem-
onstrated that the inhibition of chemotaxis by anti-a,-PI antibody was not due
to nonspecific protein binding. Moreover, because antibody to a,-PI did not
inhibit chemotaxis stimulated by FMLP, it was evident that inclusion of anti-a,-
PI antibody in the reaction mixture did not generally interfere with the ability
of neutrophils to migrate .
The chemotactic activity of proteolytically inactivated a,-PI resides in the M,
4,200 fragment (6), which is the result of hydrolysis of the Pro-357-Met-358
peptide bond (5) . When HLE forms an inhibitory complex with a,-PI, the Met-
358-Ser-359 bond is broken, resulting in a similar fragment . In both cases the
cleavage fragment is not released as a free molecule but remains associated with
the remainder of the a,-PI molecule in a rearranged position (6, 12) . To deter-
FIGURE 5. Neutrophil chemotaxis
before and after exposure to com-
petitive ligands . Neutrophils were
incubated for 30 min at ambient
temperature with 10 nM purified
HLE-a,-PI complex (light striped
bars), 10 nM purified M, 4,200 frag-
ment of a,-PI (dark striped bars), or
assay medium alone (solid bars), then
washed three times with assay
medium . The cellswere then assayed
for a chemotactic response to 1 nM
HLE-a,-PI complex, 1 nM 4,200
fragment, or 10 nM FMLP . The
data represent an average of tripli-
cate determinations, and the error
bars represent the standard error of
the mean .BANDA ET AL.
￿
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mine if the source of the activity of the HLE-a,-PI inhibitory complex could be
localized to the region of the 4,200 fragment, the following experiments were
carried out. Neutrophils were incubated with 10 nM 4,200 fragment isolated
from proteolytically inactivated a,-PI and then washed free of unbound frag-
ment before they were tested for their chemotactic response to 1 nM HLE-a,-
PI complex. This pretreatment eliminated chemotaxis (Fig. 5) . Similarly, when
neutrophils were preincubated with 10 nM HLE-a,-PI complex, migration
toward 1 nM 4,200 fragment was eliminated. Therefore, the source of the che-
motactic activity of the HLE-a,-PI complex was the same as that of the 4,200
fragment. Preincubation with either 4,200 fragment or HLE-a,-PI complex had
no effect on migration toward 10 nM FMLP, indicating that the preincubations
did not produce a generalized decrease in the chemotactic responses of these
cells.
Discussion
The function of a,-PI is usually considered solely in light of its ability to inac-
tivate serine proteinases, especially HLE. The present study suggests that a con-
sequence of a,-PI-mediated inhibition of HLE is the generation of a chemotac-
tic signal for neutrophils. The inhibitory complex therefore becomes an
inflammatory mediator. This newly described characteristic of a,-PI is not lim-
ited to proteinase-inhibitor complexes, because proteolytically inactivated a,-PI
also seems to act as an inflammatory mediator by a similar mechanism (6) . The
data suggest that an identical site with chemotactic potential is exposed in both
HLE-a,-PI complex and a,-PI proteolytically inactivated by hydrolysis of the
Pro-357-Met-358 bond.
The local regulation of a,-PI-mediated chemotaxis may be quite complicated.
a,-PI from the circulation may diffuse into tissue and form inhibitory complexes
or become proteolytically inactivated. In addition, a,-PI may be made locally by
human monocytes (13) and macrophages (14) . It is unclear whether human
monocytes or macrophages secrete metalloproteinases that could proteolytically
inactivate a,-PI. However, neutrophil collagenase can proteolytically inactivate
a,-PI (15). Human monocytes have been reported to produce a serine elastase
similar to FILE (16) and may generate HLE-a,-PI complexes (14). Therefore,
local production of a,-PI, HLE, and eel -PI-degrading proteinases may initiate
or alter the inflammatory response.
Evidence presented in this study suggests that a single neutrophil surface
receptor binds both proteolytically inactivated a,-PI and the a,-PI in the inhib-
itory complex. The site responsible for recognition appears to reside in a
domain carboxyl to the Met-358-Ser-359 peptide bond; exposure of this area is
probably the result of the severe rearrangement of modified a,-PI (12). Satu-
ration of the receptor by preincubation with HLE-a,-PI complex prevents fur-
ther chemotaxis toward modified a,-PI but does not interfere with chemotaxis
toward an unrelated molecule, FMLP. Therefore, this as yet uncharacterized
receptor must be different from the FMLP receptor. Whether it is a receptor
for other known neutrophil chemotactic stimulants, such as C5a or LTB4,
remains to be determined.
Little is known about the fate of HLE-a,-PI complexes . a2-Macroglobulin-161 4
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proteinase complexes are cleared by a macrophage cell surface receptor (17,
18) . Although it has been suggested that HLE is transferred from a,-PI to a2-
macroglobulin (19), this is unlikely because of the nature of the HLE-a,-PI
bond. Furthermore, because binding of HLE-ce,-PI to neutrophils is directly
mediated by a,-PI, transfer to a2-macroglobulin and subsequent binding to the
a2-macroglobulin receptor does not appear likely. The putative receptor for
modified a,-PI may provide a clearance mechanism for HLE-a,-PI complexes
as well as for proteolytically inactivated a,-PI. If so, turnover of native a,-PI
would also involve this receptor.
Summary
An inhibitor-proteinase complex consisting of human a,-PI and human leu-
kocyte elastase is chemotactic for human neutrophils . The chemotactic activity
is optimal at 1 nM and is associated only with the a,-PI portion of the complex.
Neither HLE in the complex, free HLE, nor native a,-PI possesses chemotactic
activity for human neutrophils. a,-PI in complex is hydrolyzed at the Met-358-
Ser-359 bond. The chemotactic activity is associated with the M, 4,200 fragment
of a,-PI that has Ser-359 as its NH2 terminus. The region of the HLE-a,-PI
complex that stimulates chemotaxis appears to be the same as that of the M,
4,200 fragment generated by hydrolysis of the Pro-357-Met-358 bond during
proteolytic inactivation of a,-PI. The data suggest the presence of a neutrophil
surface receptor bound by a,-PI after the formation of a complex with HLE or
after proteolytic degradation. This receptor may play a role in clearance of these
modified a,-PI molecules.
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